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The assessment and planning of non-inferiority
trials for retention of effect hypotheses - towards
a general approach
M. Mielke∗ and A. Munk
Institute for Mathematical Stochastics, University of Go¨ttingen
Abstract: The objective of this paper is to develop statistical methodology for planning
and evaluating three-armed non-inferiority trials for general retention of effect hypotheses,
where the endpoint of interest may follow any (regular) parametric distribution family. This
generalizes and unifies specific results for binary, normally and exponentially distributed
endpoints. We propose a Wald-type test procedure for the retention of effect hypothesis
(RET), which assures that the test treatment maintains at least a proportion ∆ of reference
treatment effect compared to placebo. At this, we distinguish the cases where the variance
of the test statistic is estimated unrestrictedly and restrictedly to the null hypothesis, to
improve accuracy of the nominal level. We present a general valid sample size allocation
rule to achieve optimal power and sample size formulas, which significantly improve existing
ones. Moreover, we propose a general applicable rule of thumb for sample allocation and
give conditions where this rule is theoretically justified. The presented methodologies are
discussed in detail for binary and for Poisson distributed endpoints by means of two clinical
trials in the treatment of depression and in the treatment of epilepsy, respectively. R-software
for implementation of the proposed tests and for sample size planning accompanies this
paper.
Keywords and phrases: Non-inferiority, Optimal sample allocation, Retention of effect,
Three-armed clinical trials, Wald-type test, Kullback-Leibler divergence.
1. Introduction
The aim of a non-inferiority trial is to demonstrate that the efficacy of a test treatment relative to
a reference one does not fall below a clinically relevant value. For selective fundamental references
we refer to Jones et al. (1996), Ro¨hmel (1998), D’Agostino (2003) and Munk & Trampisch (2005).
In this work we focus on the direct comparison of a test and reference group. To this end, the
inclusion of a concurrent placebo group is recommended if there are no ethical concerns, i.e. the
patients are not harmed by deferral of therapy and are fully informed about alternative (see e.g.
Temple & Ellenberg (2000) and Hypericum Depression Trial Study Group (2004)), to ensure for
assay sensitivity of the trial. Such a design, including a (T)est, (R)eference and (P)lacebo group,
has been coined by Koch & Ro¨hmel (2004) as gold standard design.
Retention of effect hypothesis: To demonstrate non-inferiority in the gold standard design we
consider the retention of effect type hypothesis
H0 : θT − θP ≤ ∆ · (θR − θP )
vs. (1.1)
H1 : θT − θP > ∆ · (θR − θP ),
where θk ∈ Θ ⊆ R, k = T,R, P , is the parameter of interest, representing the efficacy of a
treatment, and ∆ ∈ [0,∞) a fixed constant expressing the amount of the active control effect
relative to placebo, which should be retained. For a discussion of various issues encountered with
the choice of ∆ we refer to Lange & Freitag (2005) and the references given there, who provide
a systematic review of 332 published non-inferiority studies. Examples for θk are (a) θk = pik the
success probability of a binary endpoint representing for example if the patient achieves remission
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(Kieser & Friede, 2007), (b) θk = λk the expectation of an exponentially distributed endpoint
representing for example the time until healing or remission (Mielke et al., 2008), (c) θk = µk the
expectation of a normally distributed endpoint representing for example the FCV (forced vital
capacity) in a trial on mildly asthmatic patients (Pigeot et al., 2003). Note, that in this set up we
presume that large values of θk are associated with higher efficacy of the treatment. Compared to
absolute hypotheses, e.g. H0 : θT ≤ θR − ∆ with ∆ > 0, the advantage of the hypothesis (1.1)
is that it is invariant with respect to rescaling or shifts of the parameters θk, i.e. the margin ∆
must not be readjusted to the changes of parametrization. Thus, the margin ∆ is standardized
in that sense and therewith it could easily be compared for different hypothesis and applications,
respectively. Further, it has an intuitive and clear interpretation. Rejecting H0 implies to claim
that the test treatment achieves at least ∆ · 100% of the active control effect, at which both are
compared relatively to placebo. Rewriting the alternative in (1.1) as
H1 : θT > ∆ · θR + (1 −∆) · θP
illustrates that in this case the test treatment effect is greater than a convex combination of the
reference and the placebo effect if 0 ≤ ∆ ≤ 1. This includes two extremal cases: For ∆ = 1 we
obtain superiority of the test treatment to the reference one (at least ∆ = 100% of the reference
effect is retained) and for ∆ = 0 superiority of the test treatment to placebo.
As mentioned above for binary endpoints a typical choice is θk = pik, the success probability.
However, in practical application also transformations of the success probability are of interest, e.g.
log(pik), pik/(1−pik), log(pik/(1−pik)) or just −pik in case of a mortality rate. For a comprehensive
discussion of several hypotheses for binary endpoints see Ro¨hmel & Mansmann (1999). In order
to formalize this we modify the hypothesis (1.1) to
H0,h(θk) : h(θT )− h(θP ) ≤ ∆ · (h(θR)− h(θP ))
vs. (1.2)
H1,h(θk) : h(θT )− h(θP ) > ∆ · (h(θR)− h(θP ))
where θk ∈ Θ ⊆ Rd, k = T,R, P , determines the distribution of our endpoints of interest. Here,
h(·) is a differentiable, strictly monotone, real-valued function on the parameter space Θ measuring
the efficiency of a treatment whereas larger values of h(·) correspond to higher efficiency. In the
following, we will omit the alternatives and only state the null hypotheses.
Aim and scope: The aim of this work is to provide a general testing methodology based onWald’s
maximum likelihood asymptotic to the general retention of effect hypotheses (1.2). This, among
others, includes the above mentioned situations as special cases. In addition, we obtain tests for
Poisson distributed endpoints (for careful discussion see Section 2.2). Moreover, we discuss the issue
of sample size planning and we provide in large generality formulas for optimal allocation of samples
and accurate approximations for the determination of sample sizes in order to guarantee a certain
power. We show that this requires the computation of Kullback-Leibler divergence minimizer in
the null hypothesis to an alternative model.
Complete test procedure: To ensure assay sensitivity of the test procedure the hypothesis (1.1)
is typically embedded in a complete test procedure, where in a first step a pretest for superiority
of either the reference or the test treatment to placebo is performed, and in a second step the non-
inferiority is investigated via (1.1). There is a vigorous discussion on which pretest is appropriate.
For example Pigeot et al. (2003) carry out a pretest for superiority of the reference treatment
to placebo, whereas Koch & Ro¨hmel (2004) perform the test for the test treatment to placebo,
because the test treatment should not be blamed when the reference treatment could not beat
placebo (Koch, 2005).
It is important to note that it turns out as a common rule that the pretest is subordinated in
the complete test procedure, in terms of that sample size planning can be performed via the non-
inferiority test without adjustment to the pretest for superiority (see e.g. Mielke et al., 2008). This
means the power of the non-inferiority test nearly coincides with the power of the complete test
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procedure for commonly used alternatives. In addition, the pretest represents a well-investigated
testing problem where the parameters of comparison coincide on the boundary of the hypothesis.
Thus, we only focus in the following on the non-inferiority hypothesis (1.1) and keep the complete
test procedure at the back of mind.
State of research: Closely related to the retention of effect hypothesis (1.1) is the hypothesis
where the treatment effect θT − θR is evaluated relative to a historic active control effect θ˜R− θ˜P ,
which could not estimated concurrently, therefore. For a comprehensive discussion we refer to
Holgrem (1999), Hauck & Anderson (1999), Hasselblad & Kong (2001), Rothmann et al. (2003)
and Hung, Wang & O’Neill (2009). The most problematic issue of such design is the necessity to
project the active control effect in the current non-inferiority trial setting (Hung, Wang & O’Neill,
2009). This issue is not present in the gold standard design, where the active control effect is
estimated concurrently.
A nonparametric version of the retention of effect hypothesis (1.1) was already considered by
Koch & Tangen (1999). Pigeot et al. (2003) consider (1.1) for normally distributed endpoints. Sub-
sequently, this type of hypothesis was discussed vigorously (see e.g. Hauschke & Pigeot, 2005) and
investigated for different types of endpoints. Koch & Ro¨hmel (2004) and Schwartz & Denne (2006)
also consider normally distributed endpoints and investigate (1.1) for θk equals the expectation
µk of the groups k = T,R, P , respectively, under homogeneity of variance between the groups.
Hasler et al. (2008) and Dette et al. (2009) extend these results to the case of heterogeneity of the
group variances. Mielke et al. (2008) consider censored, exponentially distributed endpoints. Tang
& Tang (2004) and Kieser & Friede (2007) investigate binary endpoints with θk equals the success
probability pik of each group. In contrast to the normal and exponential case for binary endpoints
sample size planning leaves open questions. In particular, the existing sample size formulas lack
in precision, i.e. a deviation between exact and aspired power (cf. Kieser & Friede, 2007). The
additional difficulties for binary endpoints are mainly due to dependency of the variance on the
parameters of interest, the success probabilities. In this work we will provide a general approach
for general parametric models which allows to close this gap for binary endpoints as a special case.
Content and organization: This paper is organized as follows. In Section 2, we discuss two
clinical trials. First a trial in the treatment of depressions by investigating if the patients achieve
remission at the treatment end (binary endpoints) measured by the Hamilton rating scale score of
depression (HAM-D) and second a study in the treatment of epilepsy by investigating the number
of seizures (Poisson distributed endpoints). In Section 3, we present the general theory and derive
a Wald-type test procedure for the generalized retention of effect hypothesis (1.2), which we denote
as Retention of Effect Wald-type Test (RET) in the following. In Section 4, we derive sample size
formulas and the (asymptotically) optimal allocation for planning a three-armed retention of effect
trial. In particular, we include the important case where the variance is estimated restrictedly to
the null hypothesis. This often improves the asymptotic approximation under the null hypothesis
(see e.g. Farrington & Manning (1990) and Tang, Tang & Wang (2007)) and therefore is very
popular in practice. For the presented sample size formulas we have determined the exact limit
of the restricted ML-estimator, which has never been considered so far. As a major result this
significantly improves the precision of the formulas, see exemplarily Table 5. The optimal allocation
when the variance is estimated unrestrictedly turns out to be
n∗T : n
∗
R : n
∗
P = 1 : ∆
σ0,R
σ0,T
: |1−∆| σ0,P
σ0,T
, (1.3)
where σ0,k is the variance within group k, k = T,R, P , under the alternative, specified later on
in (3.6). Here, n∗k denotes the number of samples assigned to group k = T,R, P . This is shown
to be valid in (essentially) any parametric family. Albeit the asymptotic power will change in
general when the variance is estimated restrictedly, we argue that the optimal allocation remains
unchanged in an asymptotic sense even when the variance is estimated restrictedly to the null
hypothesis. As the optimal allocation (1.3) depends on the choice of the alternative we show in
Section 4.1.1 that one may use the allocation 1 : ∆ : (1 − ∆) as a very general rule of thumb,
which is more appropriate in terms of power than the commonly used allocation 2:2:1 as well as
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the balanced allocation, if σ20,P /σ
2
0,T is (roughly) less than 2. It is important to note that this result
is very general valid, independent of the distribution of the endpoints and of the formulation of
the hypothesis (1.2).
In Section 5, we will revisit our examples introduced in Section 2 to demonstrate and to discuss
the results of the previous sections in detail. We show that sample size reductions and therewith
reductions in the costs of a trial with up to 20% and more are possible by reallocating to the
optimal allocation instead of a balanced or the commonly used 2:2:1 allocation. In particular, it
turns out that our sample size formula for binary endpoints improves the precision of the existing
one by Kieser & Friede (2007) significantly in terms of that the exact power is close to the aspired
one. In Section 6, we briefly comment on R-software for analysis and planning of the RET, which
we provide as supplementary material, in order to allow the reader to reproduce the presented
results and to make the presented methodology directly applicable. Finally, we conclude with a
discussion in Section 7.
2. Examples
In this section, we introduce two clinical non-inferiority trials, one in the treatment of epilepsy
and the other one in the treatment of depression, and we define retention of effect hypotheses,
which are of interest within these examples.
2.1. Binary endpoints: Treatment of depression
Binomial or binary endpoints, respectively, are most commonly used in non-inferiority trials (Lange
& Freitag, 2005). In this section we introduce a clinical trial in the treatment of depression from
Goldstein et al. (2004), which was also used by Kieser & Friede (2007) for illustration. We will
find in particular different answers concerning the planning of this study (see Section 5.1).This
randomized, double-blind trial compares duloxetine (Test treatment) to paroxetine (Reference
treatment) and Placebo with regard to efficacy and safety. In the therapy of depression, achieving
remission is the clinically desired goal (Nierenberg & Wright, 1999), whereas remission is defined
as maintaining the Hamilton rating scale score of depression (HAM-D) total score at ≤ 7. Table
1 displays for each group, k = T,R, P , the total numbers of patients and the fractions of patients,
who achieved remission at week 8 (end of treatment).
Table 1
Three-armed clinical trial in treatment of depression
No. of Patients Fraction of patients
Treatment No. of patients achieved remission achieved remission
Placebo 88 26 29.55%
Reference 84 31 36.90%
Test 86 43 50.00%
For demonstrating that duloxetine is non-inferior to the reference treatment paroxetine, follow-
ing Kieser & Friede (2007), we consider the retention of effect hypothesis with h(pik) = pik
H0,pik : piT − piP ≤ ∆ · (piR − piP ) , (2.1)
where pik represents the remission probability of treatment k = T,R, P at the end of treatment.
2.2. Poisson endpoints: Treatment of epilepsy
Typical examples of Poisson distributed endpoints can be found for example in the treatment of
angina pectoris, nausea and epilepsy, see Layard & Arvesen (1978), where the number of attacks
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are counted within a specified time interval, or in the treatment of depressions, where the (waiting)
time until healing or remission is observed (see e.g. Mielke et al., 2008). Here, we reconsider the
randomized, double blind cross-over trial in the treatment of epilepsy from Sander et al. (1990),
which compares a new treatment (lamotrigine) as an add-on treatment to a placebo add-on by
means of 18 patients. Table 2 presents the total number of seizures within the treatment weeks 9-
12. Note, that Mohanraj & Brodie (2003) highlight that for evaluating anti-epileptic drugs (AED)
as add-on treatment the standard endpoint is the manipulation in the number of seizures.
Table 2
Three-armed clinical trial in treatment of epilepsy
Mean no. of seizures
Treatment No. of Patients Total no. of seizures per patient
Placebo add-on 18 338 18.78
Reference add-on 18 295 16.39
Test add-on 18 288 16.00
As AED trials performed in the past are two-armed, either placebo- or active-controlled (for
an overview see Mohanraj & Brodie, 2003), we add for illustration purposes of our procedures an
artificial reference treatment group with equal size of 18 patients and seizures of same order of
magnitude as seizures under the test treatment, also displayed in Table 2.
We presume that the number of seizures of each patient follows a Poisson distribution deter-
mined by the group affiliation (T,R,P), i.e. the observations are from Xk1, . . . , Xknk
i.i.d.∼ Pois(λk)
for k = T,R, P with nP = nT = nR = 18. Table 2 displays the total number of seizures in
each group, Xk =
∑nk
i=1Xki, k = T,R, P . As in this setting small values of λk, representing less
seizures, are desired we choose h(λk) = −λk, which yields the retention of effect hypothesis
H0,−λk : λP − λT ≤ ∆ · (λP − λR) (2.2)
for demonstrating that the test treatment is non-inferior to the reference one.
2.3. Further examples
In Table 3 we summarize various endpoints together with some common retention of effect hy-
potheses. Moreover, we have included some models which have not been used in the context of
retention of effect hypothesis, including the Weibull- and Gamma-family. However, these end-
points are of practical interest as recent non-inferiority trials by Yakhno et al. (2006) and Gurm
et al. (2008) highlight. We will not discuss all these situations in detail, but we mention that our
methodology immediately applies to these situations.
Table 3
Survey of retention of effect hypotheses
Distribution θk h(θk) σ
2
k
Normal (Pigeot et al., 2003) (µk , τ
2) µk τ
2
Normal (Hasler et al., 2008) (µk , τ
2
k
) µk τ
2
k
Binary pik pik pik(1 − pik)
(Kieser & Friede, 2007, this work)
Binary pik log(pik/(1 − pik)) (pik(1 − pik))
−1
Exponential (Mielke et al., 2008) λk log λk 1
Poisson (this work) λk −λk λk
Gamma (α, βk) α · βk [= EXk] β
2
k
α−1
Weibull (λk , β) λk [= EXk · (Γ(1 + β
−1))−1] I11(λk , β)
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3. Wald-type test: Theory
In this section, we derive a Wald-type test procedure for the generalized retention of effect hypoth-
esis (1.2) introduced in Section 1 and discuss the estimation of the variance with restriction to the
null hypothesis. This generalizes and unifies specific results for binary, normally and exponentially
distributed endpoints. Based on this, we provide the theory for sample size planning in the next
Section 4.
Model assumptions: Let Xki for i = 1, . . . , nk be independently distributed according to a
parametric family of distributions with densities {f(θ, ·) : θ ∈ Θ}, Θ ⊆ Rd, and parameters θk ∈
Θ, k = T,R, P , where T,R and P abbreviates test, reference and placebo group, respectively.
We presume that the family of probability densities {f(θ, ·) : θ ∈ Θ} is sufficiently regular to
obtain asymptotic normality of the ML-estimators (MLE) of the parameter θ with non-singular
covariance or Fisher-information matrix, respectively, e.g. an exponential family or a family which
is differentiable in quadratic mean (van der Vaart, 1998). Moreover, none of the groups should
vanish asymptotically, i.e. for k = T,R, P and n = nT + nR + nP
nk
n
−→ wk (3.1)
holds for nR, nT , nP → ∞ and some wk ∈ ]0, 1[, the (asymptotic) proportion of the numbers of
patients in group k = T,R, P .
3.1. Retention of Effect Wald-type Test (RET)
In order to come up with a test for (1.2) we rewrite this as
H0,h(θk) : η := h(θT )−∆ h(θR) + (∆− 1)h(θP ) ≤ 0 . (3.2)
The MLE of h(θk), k = T,R, P , is obtained by plugging in the MLE θˆk of θk, which is well-
defined and asymptotically normally distributed by assumption. By the delta-method this yields
that
√
nk(h(θˆk)− h(θk)) is centered asymptotically normally distributed with variance
σ2k =
(
∂
∂θ
h(θk)
)
· I(θk)−1 ·
(
∂
∂θ
h(θk)
)T
and I the Fisher-information-matrix, i.e.
I(θ) = −Eθ
[
∂2
∂2θ
log f(θ,X)
]
.
Hence, the linear contrast
√
n(ηˆ − η), where the MLE of η is obtained by plugging in the MLE’s
θˆk, k = R, T, P , in the left hand side of (3.2), is centered asymptotically normal with variance
σ2 =
σ2T
wT
+
∆2σ2R
wR
+
(1−∆)2σ2P
wP
. (3.3)
As we have mentioned in the introduction estimation of σ2 simply by the MLE often leads to an
unsatisfactory approximation of the asymptotic normal law and various improvements have been
suggested in specific settings, mainly for the case of binary endpoints (see next section). Therefore,
we will treat the case of restricted maximum likelihood estimation as well. To this end let σˆ2ML
denote the MLE of σ2 and σˆ2RML denote the MLE with restriction to the null hypothesis, i.e. the
MLE of σ2 under the restriction in (3.2). Further let σˆ2 either denote σˆ2ML or σˆ
2
RML, see the next
Section 3.2.1 for a discussion of both estimators. Both estimators are consistent under the null
hypothesis. Thus, we obtain in order to test (3.2) as a test-statistic
T =
√
n · ηˆ
σˆ
=
√
n · h(θˆT )−∆ h(θˆR) + (∆− 1)h(θˆP )
σˆ
(3.4)
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which is asymptotically standard normally distributed at the boundary ofH0,h(θk), i.e. when η = 0.
Therefore,H0,h(θk) is to reject if T > z1−α, where z1−α is the 1−α-quantile of the standard normal
distribution and α a specified significance level. Due to the formulation of the hypothesis and the
test decision we will denote this test by Retention of Effect Wald Test (RET).
3.2. The estimators of the asymptotic variance σ2 and their limits
In some situation, e.g. for normally distributed endpoints, it is sufficient to estimate the asymp-
totic variance in (3.3) by the (unrestricted) MLE (see Pigeot et al., 2003). Roughly speaking,
this is due to the fact that the asymptotic variance of the test statistic does not depend on the
parameters h(θk) (in the normal case the mean) which only enter into the hypothesis. However,
e.g. for the case of binary endpoints the variance depends on the success probabilities itself and an
improvement in the accuracy of the asymptotic normality can be obtained by estimation restrict-
edly to the null hypothesis. This has been pointed out by Farrington & Manning (1990) for the
two sample comparison with binomial endpoints and various improvements have been suggested
since (see e.g. Chan (1998), Ro¨hmel & Mansmann (1999), Skipka et al. (2004)). For the retention
of effect hypothesis Kieser & Friede (2007) demonstrate in an extensive simulation study that the
restricted Wald-type test (Farrington & Manning’s (1990) adjustment) works satisfactorily and
clearly outperforms the unrestricted Wald-type test concerning the accuracy of the nominal level.
3.2.1. Computation of σˆ2ML and σˆ
2
RML
Typically, the variance σ2 is a continuous function of the parameters θk, k = T,R, P . Thus, the
MLE σˆ2ML is obtained by plugging the MLE’s θˆk
σˆML = σ(θˆT , θˆR, θˆP ).
In order to obtain the restricted MLE σˆ2RML the θˆk’s have to be replaced by their restricted
versions, i.e.
σˆRML = σ(θˆT,H0 , θˆR,H0 , θˆP,H0)
with
(θˆT,H0 , θˆR,H0 , θˆP,H0) = arg sup(θT ,θR,θP )∈H0,h(θk)
∑
k=T,R,P
nk∑
i=1
log f(θk, xki). (3.5)
The restricted MLEs (θˆT,H0 , θˆR,H0 , θˆP,H0) can be computed in the following way: if the unre-
stricted MLEs θˆk, k = T,R, P , are located in H0,h(θk), i.e. h(θˆT ) −∆ h(θˆR) + (∆ − 1)h(θˆP ) ≤ 0,
they coincide with the restricted MLEs. Otherwise the restricted MLEs can be determined by
restricting the likelihood function to the boundary of H0,h(θk) by means of substituting θT =
h−1(∆h(θR) + (1 −∆)h(θP )) in the common likelihood function (left hand side from (3.5)) and
maximizing this with respect to θR and θP numerically or, if possible, analytically.
3.2.2. Limits of the variance estimators
The limits of the MLEs σˆ2ML and σˆ
2
RML are crucial for sample size planning in the following
Section 4. For the derivation of the limits let us denote the true (unknown) parameters by θ
(0)
k ,
k = T,R, P , and correspondingly η(0) = h(θ
(0)
T )−∆ h(θ(0)R ) + (∆− 1)h(θ(0)P ) and
σ20,k =
(
∂
∂θ
h(θ
(0)
k )
)
· I(θ(0)k )−1 ·
(
∂
∂θ
h(θ
(0)
k )
)T
(3.6)
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for k = R, T, P and
σ20 =
σ20,T
wT
+
∆2σ20,R
wR
+
(1−∆)2σ20,P
wP
. (3.7)
The unrestricted MLE σˆ2ML is always a consistent estimator, i.e. σˆ
2
ML
a.s.−→ σ20 as n→∞. However,
the restricted MLE σˆ2RML is only consistent when the true parameters are located in the hypoth-
esis, i.e. η(0) ≤ 0. In other words, the limit of σˆ2RML is no more equal to σ20 , in general. We will
now derive the limit of the restricted MLE σˆ2RML, when the parameters are located in the alterna-
tive, i.e. η(0) > 0. This requires computation of the Kullback-Leibler-divergence (KL-divergence)
between two parameter constellations. To this end, let ζ = (θT , θR, θP ) denote any parameter in
the parameter space Θ3 ⊆ R3d and ζ(0) the true parameter. Then we define for the three-sample
case a weighted KL-divergence between ζ(0) and ζ with weights c = (cT , cR, cP ) by
K(ζ(0), ζ, c) =
∑
k=T,R,P
ck ·K(θ(0)k , θk) , (3.8)
where K(θ
(0)
k , θk) = Eθ(0)
k
[log f(θ
(0)
k , X)− log f(θk, X)] denotes the usual KL-divergence measuring
the difference between two densities. According to Theorem 2 (see Appendix A.1) the restricted
MLE ζˆH0 = (θˆT,H0 , θˆR,H0 , θˆP,H0) converges to the minimizer of the sample size weighted KL-
divergence to the true parameter, i.e.
ζˆH0
a.s.−→ ζH0
with
ζH0 = (θT,H0 , θR,H0 , θP,H0) = arg min
ζ∈H0
K(ζ(0), ζ, (wT , wR, wP )).
Therefore, the limit of the restricted MLE σˆ2RML is obtained by
σ2RML =
σ2T,H0
wT
+
∆2σ2R,H0
wR
+
(1 −∆)2σ2P,H0
wP
(3.9)
with
σ2k,H0 =
(
∂
∂θ
h(θk,H0)
)
· I(θk,H0)−1 ·
(
∂
∂θ
h(θk,H0)
)T
(3.10)
for k = T,R, P .
3.2.3. Numerical computation of σRML
For computing the minimizers θk,H0 , k = T,R, P , and therewith σRML for a parameter constella-
tion in the alternative, i.e. η(0) > 0, it is sufficient to restrict to the boundary of H0,h(θk), i.e. we
replace in the weighted KL-divergence (3.8) θT by h
−1(∆h(θR)+(1−∆)h(θP )) and then minimize
the KL-divergence with respect to θR and θP .
In practice, the analytic solution to the minimization problem of the KL-divergence may be
hard (confer the example of Poisson endpoints in Section 5.2.3) or even unfeasible to find. In
this case, numerical minimization becomes necessary. To this end, it is important to note that
the minimization of the KL-divergence often results in a convex optimization problem and fast
algorithms for convex optimization , such as the Newton-Raphson algorithm, become feasible. The
following theorem states conditions to obtain a convex optimization problem.
Theorem 1: Let −E
θ
(0)
k
[ ∂
2
∂2θ log f(θ,X)] be non-negative for all θ ∈ Θ and θ
(0)
k , k = T,R, P and
let Θ be a convex set. Further, let h−1(∆h(θR) + (1 − ∆)h(θP )) be an affine transformation in
θR and θP . Then, restricted to the boundary of the null hypothesis, the minimization in ζ of the
weighted KL-divergence (3.8) is a convex optimization problem.
The conditions of Theorem 1 are fulfilled in our examples of Poisson and binary endpoints,
which will be revisited in Section 5.
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3.3. Approximating the power function of the RET
The asymptotic normality used in Section 3.1 to derive the RET is valid for parameter constella-
tions in the hypothesis as well as for constellations in the alternative. Thus, if the variance σ2 is
estimated unrestrictedly, σˆ2 = σˆ2ML, we obtain as an approximation to the power function of the
RET, i.e. the probability of rejecting the hypothesis H0,h(θk) in (1.2), by
Pη(0) (T > z1−α) ≈ 1− Φ
(
z1−α −
√
n
η(0)
σ0
)
. (3.11)
However, estimating the variance σ2 restricted to the null hypothesis, i.e. σˆ2 = σˆ2RML, complicates
the issue and changes the power function to
Pη(0) (T > z1−α) = Pη(0)
(
T · σRML
σ0
−√n η
(0)
σ0
> z1−α · σRML
σ0
−√n η
(0)
σ0
)
≈ 1− Φ
(
z1−α · σRML
σ0
−√n η
(0)
σ0
)
. (3.12)
Note, that (3.11) can be obtained from (3.12) by means of substituting σRML by σ0.
4. Sample size formula and optimal allocation of samples
In this section, we present a sample size formula for the test of the generalized retention of effect
hypothesis H0,h(θk) (1.2) introduced in Section 1. In particular, we derive the optimal allocation
of the samples to the groups T,R and P in terms of maximizing the power of the RET under any
fixed alternative η(0).
4.1. Optimal sample allocation
In planning a trial, one typically specifies a parameter constellation η(0) in the alternative. Our
aim in this section is to optimize the allocation of samples, represented through wk, k = T,R, P ,
as in (3.1), such that the power of the test decision in (3.11) or (3.12), respectively, is maximized.
The power depends on the allocation through σ20 and σ
2
RML.
When the variance σ2 is estimated unrestricted in the test procedure (σˆ2 = σˆ2ML) we only have
to consider σ20 to investigate the influence of the allocation on the power, confer (3.11). This means
that we have to minimize σ20 in order to maximize the power. By straight forward calculations,
presented in Appendix A.3, we obtain as major and general valid result that the (asymptotically)
optimal allocation of samples for the RET is given by
n∗T : n
∗
R : n
∗
P = 1 : ∆
σ0,R
σ0,T
: |1−∆| σ0,P
σ0,T
. (4.1)
The resulting optimal minimal variance is given by
σ20,optimal = (σ0,T +∆σ0,R + |1−∆|σ0,P )2 .
Remark: For the specific case of normal endpoints with equal variances (Pigeot et al. (2003),
Schwartz & Denne (2006)) and exponentially distributed endpoints (Mielke et al., 2008) we obtain
the optimal allocation 1 : ∆ : |1−∆|, again.
When the variance σ2 is estimated under restriction to H0,h(θk) the asymptotic power in (3.12)
depends additionally on σRML/σ0 because under any alternative the restricted estimator σˆRML
is not a consistent estimator for σ0. Nevertheless, the asymptotically optimal allocation derived
for the unrestricted case is again optimal in an asymptotic sense because the power in (3.12) is
dominated by the term
√
n ·η(0)/σ0 as n grows. Hence, the allocation (4.1) derived in the previous
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section, which minimizes the variance σ0, is also the (asymptotically) optimal allocation in terms
of maximizing the power when the variance σ2 is estimated restricted to H0,h(θk).
Remark: (a) We would like to stress that this result can be applied to the case of binary endpoints
(see Section 5.1.2). This leads to different results as in Kieser & Friede (2007), who derived the
optimal allocation under the additional restriction of a fixed ratio wR/wT .
(b) The asymptotically optimal allocation presented in (4.1) should be understood as approxima-
tive for finite samples as it is customary for asymptotic results. Nevertheless, for the presented
examples in this paper we will show in Section 5 that the optimal allocation is also very accu-
rate for finite samples, e.g. for a power of 80%. However, one should be aware of the fact that,
in particular for small sample sizes, it is not guaranteed that the allocation (4.1) is optimal, in
general.
4.1.1. Rule of thumb
The asymptotically optimal sample allocation (4.1) depends on the choice of the alternative ζ(0) >
0. If one is not clear about the choice of the alternative or wants to consider more than one
alternative, we recommend to use as a rule of thumb the allocation 1 : ∆ : (1−∆). We will show
for θ
(0)
R = θ
(0)
T and 0 ≤ ∆ ≤ 1 in the Appendix A.4 that the allocation 1 : ∆ : (1 − ∆) is more
appropriate than the commonly used 2:2:1 allocation (the balanced allocation) if σ20,P /σ
2
0,T <
2.12(2.73). Note, that a lower bound for σ20,P /σ
2
0,T is not required. Moreover, this result is valid
independent of the distribution of the endpoints and of the formulation of the retention of effect
hypothesis.
4.2. Sample size computation
When the variance σ2 is estimated unrestrictedly (σˆ2 = σˆ2ML) we end up with the simplified power
formula (3.11). Thus, the minimal required total sample size to obtain a power of 1−β for a given
alternative η(0) > 0 is determined by
n1−β ≈ (z1−α + z1−β)2 ·
(
σ0
η(0)
)2
(4.2)
with σ0 defined in (3.7). When the variance σ
2 is estimated restricted to the null hypothesis
(σˆ2 = σˆ2RML) the sample size formula has to be derived from (3.12) and becomes more involved,
viz.
n1−β ≈
(
z1−α · σRML + z1−β · σ0
η(0)
)2
=
(
z1−α · σRML
σ0
+ z1−β
)2
·
(
σ0
η(0)
)2
, (4.3)
with σRML derived in (3.9). As we will see the additional term σRML/σ0 has a relevant impact
on the sample size planning.
In Figure 1 we have summarized the general strategy for sample size planning (GSSP) for the
RET when the variance σ2 is estimated with restriction to the null hypothesis. When the variance
σ2 is estimated unrestrictedly by θˆML we may omit the steps 2.-4. in Figure 1 and use the simpler
formula (4.2) in step 5. to compute the required sample size n1−β .
Remark: We stress again that the use of σRML will affect the planning of the trial significantly.
If one replaces in (4.3) σRML by σ0 this may result in a too small or too large required sample
size depending on the ratio σRML/σ0. If the ratio σRML/σ0 is greater (smaller) than one, then we
end up with a too small (large) required sample size, i.e. the resulting power is smaller (larger)
than the desired power 1− β. For example, this will be the case for Poisson distributed endpoints
(see Section 2.2) and the hypothesis (2.2). We will see in Section 5.2 that σRML/σ0 > 1 for all
parameter constellations. In contrast, for binary endpoints (see Section 2.1) and the hypothesis
(2.1), we will show in Section 5.1 that there is no strict relationship between σRML and σ0. Thus,
a wrongly specified sample size may result in a too large or too small power compared to the
aspired one.
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General strategy for sample size planning (GSSP)
Input: h(·) Measure of efficacy
θ
(0)
T
, θ
(0)
R
, θ
(0)
P
Parameter constellation in the alternative, η(0) > 0.
wT : wR : wP Allocation of samples
∆ Non-inferiority margin
α Significance level
1− β Aspired power
Procedure:
1. Compute η(0) = h(θ
(0)
T
)−∆ h(θ
(0)
R
) + (∆− 1)h(θ
(0)
P
).
2. Compute σ20 via (3.7)
σ20 =
σ20,T
wT
+
∆2 · σ20,R
wR
+
(1−∆)2 · σ20,P
wP
with σ20,k , k = T,R, P , from (3.6)
σ20,k =
(
∂
∂θ
h(θ
(0)
k
)
)
· I(θ
(0)
k
)−1 ·
(
∂
∂θ
h(θ
(0)
k
)
)T
.
3. Determine the weighted KL-divergence (3.8) for the endpoint of investigation.
4. Compute the parameter constellation θk,H0 , k = T,R, P , in the null hypothesis, which
minimizes the weighted KL-divergence to the true parameter. This can be done ana-
lytically or numerically (confer Section 3.2.3).
5. Compute
σ2RML =
σ2
T,H0
wT
+
∆2σ2
R,H0
wR
+
(1 −∆)2σ2
P,H0
wP
for θk,H0 , k = T,R, P , via (3.9) and (3.10).
6. Use formula (4.3) to compute the minimal total required sample size
n1−β ≈
(
z1−α · σRML + z1−β · σ0
η(0)
)2
.
Fig 1. General strategy for sample size planning (GSSP) when the variance σ2 is estimated with restriction to the
null hypothesis.
5. Examples revisited
In the following we will perform the RET for the examples from Section 2 and we will illustrate the
general strategy for sample size planning (GSSP) including a detailed investigation of the optimal
allocation.
5.1. Binary endpoints: Treatment of depression
In this section, we revisit the example in the treatment of depression introduced in Section 2.1.
5.1.1. Performing the RET
For the sake of completeness we recall the RET for the situation h(pik) = pik, which was already in-
troduced by Tang & Tang (2004) and Kieser & Friede (2007). The MLE of pik is pˆik = n
−1
k
∑nk
i=1Xki
which is asymptotically normally distributed with variance σ2k = pik(1−pik). Hence, the unrestricted
MLE of the variance σ2 is given by (cf. (3.3)),
σˆ2ML = n ·
(
pˆiT (1− pˆiT )
nT
+∆2
pˆiR(1 − pˆiR)
nR
+ (1−∆)2 pˆiP (1 − pˆiP )
nP
)
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Fig 2. Example of binary distributed endpoints: Sample size reduction in % when optimal allocation (5.3) is used
instead of the balanced allocation (right figure) and instead of the allocation 2:2:1 (left figure) for pi0,P = 0.1 and
different values ∆ = 0.5 (dotted line), ∆ = 0.6 (dashed line), ∆ = 0.7 (dotdash line), ∆ = 0.8 (solid line).
and we end up with the test statistic (see (3.4))
T =
√
n · pˆiT −∆ pˆiR + (∆− 1)pˆiP
σˆML
(5.1)
in order to test H0,pik in (2.1), which is rejected if T > z1−α.
Let us now consider the case where σ2 is estimated restrictedly (cf. Farrington & Manning,
1990). The restricted version of the Wald-type test is observed by replacing the MLEs pˆik in
the denominator by the to H0,pik restricted ones. Here, we have computed the restricted MLEs
accordingly to Section 3.2.1 by means of substituting piT = ∆piR + (1 − ∆)piP in the common
likelihood function and maximizing this with respect to piR and piP numerically. Note, that in
contrast to the two-sample case (Farrington & Manning, 1990), an analytical computation of the
restricted MLE’s is not feasible, anymore.
The RET for the hypothesis (2.1) with ∆ = 0.8 yields T = 2.104 (2.108) in (5.1) using the
restricted (unrestricted) estimator for the variance estimation and corresponding p-values 1.77%
(1.75%). Thus, we would reject H0,θk from (2.1) in both cases and claim that the test treatment
duloxetine is non-inferior to paroxetine.
5.1.2. Optimal allocation
For binary distributed endpoints and the hypothesis (2.1) the optimal allocation of samples is
given by
n∗T : n
∗
R : n
∗
P = 1 : ∆
√
pi0,R(1− pi0,R)
pi0,T (1− pi0,T ) : |1−∆|
√
pi0,P (1− pi0,P )
pi0,T (1− pi0,T ) (5.2)
according to (4.1). For the commonly used alternative pi0,R = pi0,T the allocation simplifies to
n∗T : n
∗
R : n
∗
P = 1 : ∆ : |1−∆|
√
pi0,P (1− pi0,P )
pi0,T (1− pi0,T ) . (5.3)
In contrast to the case of normally distributed endpoints, where the optimal allocation is given
by 1 : ∆ : |1 − ∆| (cf. Pigeot et al., 2003), the optimal allocation depends on the parameter of
investigation.
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Table 4
Example of binomial distributed endpoints: Optimal sample allocation, limit of variance estimator σˆRML and
required samples size from formula (4.3) and (4.2), respectively, to obtain a power of 0.7 and 0.8, respectively,
when the variance σ2 is estimated restrictedly to the null-hypothesis (unrestrictedly), where α = 5%, ∆ = 0.7.
Optimal allocation 2:2:1 allocation
pi0,P pi0,T w
∗
T
w∗
R
w∗
P
σRML
σ0
n0.7 n0.8
σRML
σ0
n0.7 n0.8
0.1 0.3 0.527 0.369 0.104 0.994 997 (988) 1308 (1297) 1.014 1054 (1076) 1388 (1414)
0.5 0.532 0.372 0.096 0.986 296 (289) 387 (380) 1.006 315 (318) 415 (418)
0.7 0.527 0.369 0.104 0.955 118 (110) 154 (145) 0.965 127 (120) 165 (158)
0.9 0.500 0.350 0.150 0.791 43 (30) 54 (39) 0.759 48 (31) 60 (41)
0.3 0.5 0.506 0.354 0.139 0.998 1279 (1275) 1680 (1675) 1.012 1341 (1341) 1761 (1762)
0.7 0.500 0.350 0.150 0.986 281 (275) 368 (361) 0.975 298 (287) 390 (377)
0.9 0.463 0.324 0.212 0.867 76 (61) 98 (81) 0.830 84 (63) 106 (83)
0.5 0.7 0.493 0.345 0.161 0.997 1134 (1129) 1489 (1483) 0.988 1191 (1170) 1561 (1537)
0.9 0.455 0.318 0.227 0.924 161 (143) 209 (188) 0.894 174 (147) 224 (193)
0.7 0.8 0.489 0.343 0.168 0.998 3505 (3495) 4603 (4591) 0.989 3672 (3611) 4814 (4744)
0.9 0.463 0.324 0.212 0.974 571 (549) 746 (721) 0.949 609 (562) 792 (739)
0.8 0.9 0.476 0.333 0.190 0.992 2101 (2076) 2756 (2727) 0.975 2214 (2130) 2895 (2798)
Kieser & Friede (2007) derived the optimal allocation under the additional constraint that the
test and reference group are balanced, n∗T = n
∗
R. Our result (5.2) shows that this restriction does
not lead to an approximative optimal allocation, in general. Exemplary, Kieser & Friede (2007)
derive that the allocation 2.1 : 2.1 : 1 would be optimal for piP = 0.1, piT = piR = 0.9 and ∆ = 0.6,
whereas (5.3) yields an optimal allocation of 2.5 : 1.5 : 1, giving more weight to the test group
relative to the reference group and nearly the same to the placebo group. The allocation 2.5 : 1.5 : 1
and the allocation 2.1 : 2.1 : 1 result in a total required sample size of 79 and 89, respectively, when
a power 1 − β of 80% is desired. Thus, our optimal allocation makes a further reduction of total
sample size of about 12% possible in this specific setting. The sample size reductions which are
possible in other settings are illustrated in Figure 2, where the reduction for the optimal allocation
instead of a balanced and a 2:2:1 allocation, respectively, is presented for pi0,P = 0.1 and different
values of ∆, exemplary. For the 2:2:1 allocation we observe reductions between about 3% and 10%.
For the balanced allocation there are reductions up to 20% and more possible. Thus, the 2:2:1
allocation is more apporiate than the balanced allocation. However, it can be further improved by
the optimal one (5.3).
5.1.3. Planning a trial - applying the GSSP
For binary distributed endpoints the weighted KL-divergence is given by
K(ζ(0), ζ, w) =
∑
k=T,R,P
wk ·
(
pi
(0)
k · log
pi
(0)
k
pik
+ (1− pi(0)k ) · log
1− pi(0)k
1− pik
)
(5.4)
with ζ = (piT , piR, piP ) and ζ
(0) = (pi
(0)
T , pi
(0)
R , pi
(0)
P ). We restrict our investigations in the following to
the commonly used alternative pi
(0)
T = pi
(0)
R . To restrict the minimization problem of the weighted
KL-divergence to H0,pik (2.1) we substitute piT = ∆piR + (1 −∆)piP in (5.4). We have minimized
the KL-divergence (5.4) in piR and piP by the Newton-Raphson algorithm, confer Section 3.2.3.
Note, that this is a strictly convex optimization problem by Theorem 1 because
−E
pi
(0)
k
[
∂2
∂2pi
log f(pi,X)
]
=
pi
(0)
k
pi2
+
1− pi(0)k
(1 − pi)2 > 0
for any pi and pi
(0)
k . This guarantees the existence of a unique minimizer and geometric convergence
of the Newton-Raphson algorithm. Based on the obtained results the limit σ2RML of the restricted
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Table 5
Precision of sample size formula (4.3) and comparison to the results obtained by Kieser & Friede (2007) for a
aspired power of 80% at significance level α = 2.5%.
Usage of Eq. (4.3) from this
Kieser & Friede (2007) work with exact limit σRML
wT : wR : wP ∆ pi0,P pi0,R n Exact Power n Exact Power
1:1:1 0.6 0.1 0.5 309 78.94% 319 80.08%
0.1 0.7 135 81.51% 132 80.77%
0.1 0.9 54 83.05% 53 80.49%
0.3 0.7 318 81.17% 312 80.45%
0.3 0.9 99 83.92% 94 81.52%
0.5 0.9 213 84.95% 195 81.43%
0.8 0.1 0.7 606 81.74% 583 80.18%
0.1 0.9 201 85.57% 182 81.14%
0.3 0.9 345 85.39% 309 81.08%
0.5 0.9 726 84.74% 653 80.51%
2:2:1 0.6 0.1 0.5 270 78.59% 283 80.36%
0.1 0.7 115 79.96% 119 80.62%
0.1 0.9 50 84.71% 49 80.71%
0.3 0.7 290 80.73% 287 80.02%
0.3 0.9 95 84.25% 89 80.82%
0.5 0.9 213 86.06% 186 81.11%
0.8 0.1 0.7 510 81.69% 492 80.15%
0.1 0.9 170 85.42% 156 81.99%
0.3 0.9 300 85.51% 269 81.09%
0.5 0.9 635 84.69% 575 80.88%
3:2:1 0.6 0.1 0.5 252 78.15% 268 80.49%
0.1 0.7 108 80.54% 110 81.05%
0.1 0.9 42 80.12% 45 83.09%
0.3 0.7 276 80.97% 272 80.31%
0.3 0.9 90 85.70% 83 81.07%
0.5 0.9 204 87.31% 173 80.65%
0.8 0.1 0.7 486 82.51% 458 80.17%
0.1 0.9 156 87.36% 135 81.75%
0.3 0.9 282 87.17% 241 81.21%
0.5 0.9 606 86.02% 520 80.30%
MLE’s of the variance is computed and compared to the true variance σ20 , see Table 4, columns 6
and 9. We used throughout Table 4 a choice of ∆ = 0.7, exemplary.
We may use (4.2) and (4.3), respectively, to compute the total required sample sizes. The results
are also displayed in Table 4 for a power 1−β of 0.7 and 0.8, respectively, for the optimal allocation,
displayed in the columns 3-5 of Table 4, and the commonly used 2:2:1 allocation for the purpose
of illustrating the influence of allocation on the total required sample size. The sample size values
in brackets are determined by (4.2), i.e. the RET is performed with unrestricted estimation of
variance σˆ2 = σˆ2ML, and the values in front without brackets are determined by (4.3), i.e. the
RET is performed with restricted estimation of variance σˆ2 = σˆ2RML. For large sample sizes the
differences between both values are relatively small, whereas for small to moderate sample sizes
(n < 200) the differences are more pronounced. The amount of difference is driven by the difference
between σRML and σ0, see again Table 4, column 6 and 9.
It is important to note, that these results differ from those obtained by Kieser & Friede (2007).
This is due to the fact, that for the computation of σ2RML we have used the limit of the restricted
MLE σˆ2RML instead of choosing an arbitrary parameter constellation on the boundary of H0,pik .
We will see that the usage of the exact limit σ2RML improves significantly the precision of the
sample size formula (4.3). To this end, we have determined the required total sample size n via
(4.3) with usage of the exact limit σ2RML to obtain a power of 80% at level α = 2.5% (in order
to be comparable with the results obtained by Kieser & Friede (2007)) for different parameter
settings and allocations and thereafter we have computed the resulting exact power (see Table
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Fig 3. Example of Poisson distributed endpoints: Sample size reduction in % when optimal allocation is used
instead of the balanced allocation (right figure) and instead of the allocation 2:2:1 (left figure) for different values
of ∆, ∆ = 0.5 (dotted line), ∆ = 0.6 (dashed line), ∆ = 0.7 (dotdash line), ∆ = 0.8 (solid line).
5). Note, that we always have rounded down the group sample sizes nk, k = T,R, P . The results
obtained by Kieser & Friede (2007), who have not used the exact limit σ2RML, are displayed for
comparison. Kieser & Friede (2007) obtain an exact power that increases to 85% or even to 87%
for some settings although n > 200. Whereas the power decreases up to 78% for other settings.
In contrast, our method results in power values between 80% and 82% for all settings (with one
exception for the case wT : wR : wP = 3 : 2 : 1, ∆ = 0.6, pi0,P = 0.1 and pi0,R = 0.9 due to the
small total sample size of 45). In summary, we find that our approximative formula yields very
satisfactory results over a broad range of scenarios.
5.2. Poisson endpoints: Treatment of epilepsy
In this section, we revisit the example in the treatment of epilepsy introduced in Section 2.2.
5.2.1. Performing the RET
The MLE λˆk is obtained by the mean value n
−1
k
∑nk
i=1Xki, which is asymptotically normally
distributed with variance σ2k = λk. The unrestricted MLE of the variance σ
2 is obtained by
σˆ2ML = n ·
(
λˆT
nT
+∆2
λˆR
nR
+ (1−∆)2 λˆP
nP
)
.
Hence, we end up with the test statistic (see (3.4))
T =
−λˆT +∆λˆR + (1−∆)λˆP√
λˆT
nT
+∆2 λˆRnR + (1−∆)2
λˆP
nP
(5.5)
in order to test H0,−λk from (2.2), where H0,−λk is rejected if T > z1−α. The restricted version
of the Wald-type test is observed by replacing the MLEs λˆk in the denominator by the to H0,−λk
restricted ones. Again, we have computed the restricted MLEs numerically as for binary endpoints
in the previous section.
The RET for the hypothesis (2.2) with ∆ = 0.5 yields T = 1.328 (1.349) in (5.5) using the
restricted (unrestricted) estimator for the variance estimation and corresponding p-values 9.21%
(8.86%). Thus, we would not reject H0,−λk from (2.2) at level α = 0.05 and we could not claim
that the test treatment is non-inferior to the reference one.
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5.2.2. Optimal allocation
Table 6
Optimal allocation of samples for the example of Poisson distributed endpoints
∆ = 0.5 ∆ = 0.7 ∆ = 0.8
λ0,T
λ0,P
=
λ0,R
λ0,P
w∗
T
w∗
R
w∗
P
w∗
T
w∗
R
w∗
P
w∗
T
w∗
R
w∗
P
0.9 0.49 0.25 0.26 0.50 0.35 0.16 0.50 0.40 0.10
0.8 0.49 0.24 0.27 0.49 0.34 0.16 0.49 0.40 0.11
0.7 0.48 0.24 0.28 0.49 0.34 0.17 0.49 0.39 0.12
0.6 0.47 0.23 0.30 0.48 0.34 0.19 0.49 0.39 0.13
0.5 0.45 0.23 0.32 0.47 0.33 0.20 0.48 0.38 0.14
0.3 0.41 0.21 0.38 0.44 0.31 0.24 0.46 0.37 0.17
0.2 0.38 0.19 0.43 0.42 0.30 0.28 0.44 0.36 0.30
For Poisson distributed endpoints and the hypothesis (2.2) the optimal allocation of samples is
given by
n∗T : n
∗
R : n
∗
P = 1 : ∆
√
λ0,R
λ0,T
: |1−∆|
√
λ0,P
λ0,T
. (5.6)
Table 6 presents the optimal allocation for the commonly used alternative λ0,T = λ0,R for different
choices of λ0,T /λ0,P = λ0,R/λ0,P and ∆. Note, that we may assume w.l.o.g λ0,P = 1 because
multiplication of all parameters λ0,k, k = T,R, P , by the same factor does not change the optimal
allocation. This simplifies computation significantly. The sample size reductions which are possible
are illustrated in Figure 3 where the reduction for using the optimal allocation instead of a balanced
and a 2:2:1 allocation, respectively, is presented for different values of ∆. The results are quite
similar to the ones for binary endpoints in the previous section.
Table 7
Example of Poisson distributed endpoints: Limits of restricted MLE’s, limit of variance estimator σˆRML and
required samples size to obtain a power of 0.7 and 0.8, respectively, when the variance is estimated restrictedly to
the null-hypothesis (unrestrictedly), a nominal significance level α = 5%, for different parameter constellations
and choices of ∆ for the optimal sample allocation in (5.6).
∆
λ0,T
λ0,P
=
λ0,R
λ0,P
λT,H0
λ0,P
λR,H0
λ0,P
λP,H0
λ0,P
σRML
λ0,P
σ0
λ0,P
σRML
σ0
n0.7 · λ0,P n0.8 · λ0,P
0.5 0.7 0.78 0.64 0.92 1.763 1.755 1.005 649 (645) 852 (847)
0.5 0.64 0.41 0.87 1.594 1.561 1.021 190 (184) 248 (241)
0.3 0.51 0.21 0.81 1.426 1.322 1.079 76 (68) 98 (89)
0.7 0.7 0.75 0.66 0.95 1.726 1.722 1.002 1729 (1724) 2270 (2265)
0.5 0.58 0.44 0.91 1.515 1.502 1.009 479 (472) 628 (620)
0.3 0.42 0.23 0.86 1.278 1.231 1.038 172 (162) 224 (213)
0.8 0.7 0.73 0.67 0.97 1.707 1.706 1.001 3810 (3805) 5004 (4999)
0.5 0.55 0.46 0.94 1.479 1.473 1.004 1028 (1021) 1349 (1342)
0.3 0.38 0.25 0.90 1.210 1.186 1.020 348 (338) 456 (444)
5.2.3. Planning a trial - applying the GSSP
For Poisson distributed endpoints the weighted KL-divergence is given by
K(ζ(0), ζ, w) =
∑
k=T,R,P
wk ·
(
λk − λ(0)k + λ(0)k ·
(
logλ
(0)
k − logλk
))
(5.7)
with ζ = (λT , λR, λP ) and ζ
(0) = (λ
(0)
T , λ
(0)
R , λ
(0)
P ). In the following we restrict our investigations to
the commonly used alternative λ
(0)
T = λ
(0)
R . To restrict the minimization problem of the weighted
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KL-divergence to the boundary of H0,−λk (2.2) we substitute λT = ∆λR + (1 − ∆)λP in (5.7).
For this situation, an explicit minimization of the KL-divergence is possible. To this end, we
evaluate the derivatives of K w.r.t. λR and λP at zero which is extremely cumbersome and yields
a rather complex solution (see A.5). The KL-divergence minimizer over H0,−λk , denoted by λk,H0 ,
k = T,R, P , are displayed in Table 7 (columns 3-5) for different parameter constellations and
choices of ∆. Based on these results the limit σ2RML of the restricted MLE’s of the variance is
computed (column 6) and compared to the true variance σ20 , see Table 7 columns 7 and 8. We
presumed throughout Table 7 the usage of the optimal allocation from Table 6. In addition, for
all parameter constellations the required total samples size n0.7, n0.8 to obtain a power of 0.7 and
0.8, respectively, are computed via (4.2) (values in brackets) and (4.3), respectively. Note, that
n1−β · λ0,P is displayed in Table 7 and thus the displayed values have to be divided by λ0,P to
obtain the required total sample sizes.
6. Software
We provide the R source code of functions and documentation for planning and analyzing the
RET for various endpoints as supplementary material (File: RET.Package.pdf ). This covers bi-
nary (Section 5.1), Poisson (Section 5.2), normally (Pigeot et al., 2003) and censored, exponentially
distributed endpoints (Mielke et al., 2008). All provided functions have the following common
structure:
RET.xx.yy( ) Performs the RET for given data
RET.xx.yy.OptAlloc( ) Computes the optimal sample allocation for the RET
RET.xx.yy.Samplesize( ) Determines the required sample sizes for the RET
where ’xx’ specifies the distribution of the endpoints and ’yy’ the retention of effect hypothesis.
7. Discussion
In this paper, we have presented a full analysis and planning of three-armed trials for general
retention of effect hypotheses. The endpoint of interest may follow any (regular) parametric dis-
tribution family. As a major result, we have derived the asymptotically optimal allocation, see
Equation (4.1), and sample size formulas for planning the trial (4.2) and (4.3) for restricted as
well as unrestricted estimation of the variance. To this end, the crucial step was the determination
of the exact limit σ2RML of the restricted MLE of the variance σ
2, which was not investigated
and incorporated in this context so far to our knowledge. As a consequence, note that for plan-
ning a non-inferiority trial it is important to decide in advance which estimation method will be
performed as it affects the power and hence the total number of samples required.
For binomial endpoints this improves on existing procedures. This includes the precision of the
sample size formula as well as the issue of optimal allocation. The optimal allocation reduces the
total sample size by amounts up to 10% (20%) compared to the 2:2:1 (balanced) allocation. In
addition, the methods of this paper are applied to Poisson endpoints, which were not investigated
in the context of three-armed non-inferiority trials so far to our knowledge.
A problematic issue might be that the sample size planning and evaluation of a study presented
in this paper is based on asymptotically considerations. Thus, for finite samples the optimal
allocation could differ. In both examples investigated in this paper this is not the case, at least
numerical studies show that the differences are irrelevantly small. However, differences could occur
for example when the ratio σRML/σ0 is far away from 1 and the signal to noise ratio η(0)/σ0 is
very small.
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Appendix A
A.1. Limit of the restricted MLE
Assumption 1 : For ζ(0) in the alternative H1 and nk/n → wk ∈]0, 1[, w = (wT , wR, wP ), the
minimum ζH0 = (θT,H0 , θR,H0 , θP,H0) = argminζ∈H0 K(ζ
(0), ζ, w) is well-defined.
Assumption 2 : For any sequence ζ(n) = (θ
(n)
T , θ
(n)
R , θ
(n)
P ) in H0 with limn→∞ ζ
(n) in Θ
3 \ Θ3 or
with limn→∞ ‖ ζ(n) ‖=∞
lim
n→∞
∏
k=T,R,P
f(θ
(n)
k , xk) = 0
holds P ζ
(0)
almost everywhere.
The next theorem shows that the restricted MLE converges to the minimizer of the sample
size weighted Kullback-Leibler-divergence (KL-divergence) with respect to the true parameter,
denoted by θk,H0 , k = T,R, P .
Theorem 2: Let ζˆH0n denote the MLE restricted to H0. Then under the Assumptions 1 and 2
ζˆH0n
a.s.−→ ζH0 .
Proof. Let
Qn(ζ) = −
∑
k=T,R,P
1
n
nk∑
i=1
log f(Xki, θk)
and
Q(ζ) = −
∑
k=T,R,P
wk · Eθ(0)
k
[log f(Xk1, θk)].
Note, that by definition
K(ζ(0), ζ, w) = Q(ζ)−Q(ζ(0))
holds and consequently ζH0 = argminζ∈H0 K(ζ
(0), ζ, w) is also the well-defined minimizer of Q(ζ)
in H0.
Assumption 2 ensures that the MLE is asymptotically almost surely located in a compact set,
i.e. there exists compact subset H˜0 such that
lim
n→∞
ζˆH0n = limn→∞
ζˆH˜0n a.s.
A proof for limn→∞ ‖ ζ(n) ‖= ∞ can be found in Wald (1949). However, for limn→∞ ζ(n) in
Θ
3 \Θ3 this can be proved analogously. Hence, we assume w.l.o.g. that H0 is compact. Therefore,
the convergence
Qn(ζ)
a.s.−→ Q(ζ)
is uniformly in H0 (see Jennrich, 1969,Theorem 2) and we can apply Lemma 2.2 from White
(1980), which yields that ζˆH0n = argminζ∈H0 Qn(ζ) converges almost surely to the well-defined
minimum ζH0 of Q(ζ) in H0.
A.2. Proof of Theorem 1
The condition −E
θ
(0)
k
[ ∂
2
∂2θ log f(θ,X)] ensures that the KL-divergence K(θ
(0)
k , θ) is a convex func-
tion in θ for θ
(0)
k , k = T,R, P . Thus, the weighted KL-divergence
K(ζ(0), (θT , θR, θP ), c) =
∑
k=T,R,P
ck ·K(θ(0)k , θk)
Mielke & Munk /Evaluating and planning the RET 19
is convex in the arguments θk, k = T,R, P . Let us denote
g(θR, θP ) = h
−1(∆h(θR) + (1−∆)h(θP )),
which is an affine transformation in both arguments by assumption. Hence,
K(θ
(0)
T , g(θR, θP ))
is a convex function in (θR, θP ). Therefore, the weighted KL-divergence with restriction to the
boundary of the null hypothesis H0,h(θk) represented by
K(ζ(0), (g(θR, θP ), θR, θP ), c) = cT ·K(θ(0)T , g(θR, θP )) + cR ·K(θ(0)R , θR) + cP ·K(θ(0)P , θP )
is a linear combination of convex function and therewith convex in (θR, θP ), again.
A.3. Minimization of σ2
0
as a function of sample allocation
As the sample allocation has to fulfill wT +wR+wP = 1 we substitute wP = 1−wT −wR in (3.7)
and obtain
σ20 =
σ20,T
wT
+
∆2 · σ20,R
wR
+
(1 −∆)2 · σ20,P
1− wT − wR .
Note, that σ20 is convex function in (wT , wR). Evaluating the derivatives of σ
2
0 w.r.t. wT and wR
at zero yields
∂
∂wT
σ20 =
(1−∆)2 · σ20,P
(1 − wR − wT )2 −
σ20,T
w2T
= 0
∂
∂wR
σ20 =
(1−∆)2 · σ20,P
(1 − wR − wT )2 −
∆2 · σ20,T
w2T
= 0.
Solving the equations for wT and wR yields the minimizer
w∗T =
σ0,T
σ0,T +∆ · σ0,R + |1−∆| · σ0,P
w∗R =
∆ · σ0,R
σ0,T +∆ · σ0,R + |1−∆| · σ0,P
and therewith
w∗P =
|1−∆| · σ0,P
σ0,T +∆ · σ0,R + |1−∆| · σ0,P .
Thus, the optimal allocation in terms of minimizing the variance σ20 is given by
n∗T : n
∗
R : n
∗
P = w
∗
T : w
∗
R : w
∗
P = 1 : ∆
σ0,R
σ0,T
: |1−∆| σ0,P
σ0,T
.
A.4. Comparison of the variance σ2
0
for different allocations
Theorem 3: If θ
(0)
R = θ
(0)
T and σ
2
0,P /σ
2
0,T < 2.12 then the allocation 1 : ∆ : (1 −∆) results in a
smaller variance σ20 (3.7) (and hence larger asymptotic power) than the allocation 2:2:1 for any
0 ≤ ∆ ≤ 1.
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Proof. Substituting the allocation 2:2:1 and 1 : ∆ : (1 − ∆), respectively, and θ(0)R = θ(0)T in the
variance σ20 from (3.7) yields
σ22:2:1 =
5 + 5∆2
2
σ20,T + 5(1−∆)2 σ0,P
and
σ21:∆:1−∆ = 2(1 + ∆) σ
2
0,T + 2(1−∆) σ20,P .
Thus, we obtain with r := σ20,P /σ
2
0,T > 0
g(∆, r) :=
σ22:2:1 − σ21:∆:1−∆
σ20,T
= (2.5 + 5 · r)∆2 + (−2− 8 · r)∆ + (0.5 + 3 · r) ,
which is as a quadratic function in ∆ with minimum
(a(r), b(r)) =
(
2 + 8 · r
5 + 10 · r ,
−4 · (r − 2.11803)(r+ 0.118034)
10 + 20 · r
)
,
where 0 < a(r) < 1 and b(r) > 0 for r < 2.11803 ≈ 2.12. Thus, we obtain for r = σ20,P /σ20,T < 2.12
that g(∆, r) > 0, which implies σ22:2:1 > σ
2
1:∆:1−∆, for any 0 ≤ ∆ ≤ 1.
Theorem 4: If θ
(0)
R = θ
(0)
T and σ
2
0,P /σ
2
0,T < 2.73 then the allocation 1 : ∆ : (1 −∆) results in a
smaller variance σ20 (3.7) (and hence larger asymptotic power) than the balanced allocation 1:1:1
for any 0 ≤ ∆ ≤ 1.
Proof. Substituting the allocation 1:1:1 and 1 : ∆ : (1 − ∆), respectively, and θ(0)R = θ(0)T in the
variance σ20 from (3.7) yields
σ21:1:1 = (3 + 3∆
2) σ20,T + 3(1−∆)2 σ0,P
and
σ21:∆:1−∆ = 2(1 + ∆) σ
2
0,T + 2(1−∆) σ20,P .
Thus, we obtain with r := σ20,P /σ
2
0,T > 0
g(∆, r) :=
σ21:1:1 − σ21:∆:1−∆
σ20,T
= (3 + 3 · r)∆2 + (−2− 4 · r)∆ + (1 + r) ,
which is as a quadratic function in ∆ with minimum
(a(r), b(r)) =
(
2 + 4 · r
6 + 6 · r ,
−(r − 1 +√3)(r − 1−√3)
3 + 3 · r
)
,
where 0 < a(r) < 1 and b(r) > 0 for r < 1 +
√
3 ≈ 2.73. Thus, we obtain for r = σ20,P /σ20,T < 2.73
that g(∆, r) > 0, which implies σ21:1:1 > σ
2
1:∆:1−∆, for any 0 ≤ ∆ ≤ 1.
A.5. Poisson example: weighted KL-divergence minimizer
An analytical solution to the minimization of the KL-divergenceK(ζ(0), ζ, w) for Poisson endpoints
in Section 5.2.3 can be obtained by evaluating the derivatives of KL-divergence (5.7) w.r.t. λR and
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λP at zero after substituting λT = ∆λR + (1−∆)λP , which yields
λR,H0 =
[
∆2(−1 + wT )wTλ0,P −∆(−1 + wT )wT (λ0,P − λ0,T ) + w2R((−1 + ∆)λ0,P + (2−∆)λ0,T )
+ wR((−1 + ∆)(−1 + wT +∆wT )λ0,P + (−∆+ wT + 2∆wT −∆2wT )λ0,T )− S
]
/ (2(wR +∆(−1 + wT ))(wR +∆wT ))
λP,H0 =
[
w2Rλ0,P +∆
2wT ((−1 + wR + wT )λ0,P − wRλ0,T ) + wR((−1 + wT )λ0,PwTλ0,T )
+ ∆((2 + w2R − 3wT + w2T + wR(−3 + 2wT ))λ0,P + (wR − w2R + wT − w2T )λ0,T )− S
]
/
(
2((−1 + wR)wR +∆2(−1 + wT )wT +∆(1− wT + wR(−1 + 2wT )))
)
λT,H0 = ∆λR,H0 + (1−∆)λP,H0
with
S =
{−4∆(−1 + wR + wT )((−1 + wR)wR +∆2(−1 + wT )wT +∆(1− wT + wR(−1 + 2wT )))λ0,P
· ((−1 + wR + wT )λ0,P − (wR + wT )λ0,T ) + (∆2wT ((−1 + wR + wT )λ0,P − wRλ0,T )
+ wR((−1 + wR + wT )λ0,P − wTλ0,T ) + ∆((2 − 3wR + w2R − 3wT + 2wRwT + w2T )λ0,P
+ (wR − w2R + wT − w2T )λ0,T ))2
}1/2
.
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